> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Innoviva Reverses $38.9 Million Foreign Tax Reserve, Softening A $73.9 Million Quarterly Loss
- URL: https://www.bullished.co/innoviva-reverses-38-9-million-foreign-tax-reserve-softening-a-73-9-million-quarterly-loss-7d2ad0ab/
- Published: 2026-11-04T22:48:37.000Z
- Updated: 2026-11-04T22:48:37.000Z
- Description: A lapsed statute of limitations pushed the nine-month tax rate to negative 1.2% as Armata markdowns drove the third-quarter loss.
- Author: Matteo Parrino
- Tags: Earnings, INVA, Industry: Healthcare

[Innoviva](https://www.bullished.co/tag/inva/), which collects royalties on GSK respiratory inhalers and sells its own hospital medicines, [reversed a $38.9 million reserve](https://www.sec.gov/Archives/edgar/data/0001080014/000119312526447384/inva-20260930.htm?ref=bullished.co) for potential foreign tax liabilities in the third quarter, after the statute of limitations expired. The release produced a $23.7 million tax benefit and cushioned a net loss of $73.9 million, or $1.03 per basic share, that stemmed from losses on its Armata Pharmaceuticals stake.

## A tax item against an Armata hit

Innoviva's pre-tax loss for the quarter was $97.6 million. Unrealized losses of $97.6 million on its Armata common stock and warrants, tied to swings in Armata's share price, accounted for that figure, according to the 10-Q filed Wednesday.

The nine-month effective tax rate came in at (1.2)%, against 18.8% a year earlier. The [prior quarterly filing](https://www.sec.gov/Archives/edgar/data/0001080014/000119312526335235/inva-20260630.htm?ref=bullished.co) put the six-month rate at 18.5%.

The reversal shows up on the balance sheet. Other assets fell to $0.8 million from $40.7 million at December 31, and long-term income tax payable dropped to $19.4 million from $57.0 million.

## Operations grew, investments dragged

Net unfavorable fair-value changes in equity and long-term investments totaled $139.5 million for the quarter, mostly from a drop in Armata's stock price at quarter-end, the company said in its [earnings release](https://www.sec.gov/Archives/edgar/data/0001080014/000119312526447366/d177079dex991.htm?ref=bullished.co). Strategic investments stood at $535.5 million, including $323.7 million in Armata. Innoviva owned 67.4% of Armata at September 30.

[Operating income rose 21.9%](https://markets.ft.com/data/announce/detail?dockey=600-202611041605BIZWIRE%5FUSPRX%5F%5F%5F%5F20261104%5FBW246173-1&ref=bullished.co) to $42.2 million. U.S. net product sales climbed 45% to $43.3 million, led by $23.1 million from GIAPREZA and $16.1 million from XACDURO. Total revenue slipped 1.6% to $106.1 million, with gross GSK royalties flat at $58.1 million.

Over the first nine months, net income was $29.3 million, or $0.40 per share.

## Cash, buybacks and a new payment

Cash and equivalents totaled $581.4 million. The company bought back [1,226,948 shares](https://markets.ft.com/data/announce/detail?dockey=600-202611041605BIZWIRE%5FUSPRX%5F%5F%5F%5F20261104%5FBW246173-1&ref=bullished.co) at a cost of $26.3 million this quarter, lifting cumulative repurchases under the $125 million program to $82.7 million.

The 10-Q also says a $10.0 million milestone owed to AstraZeneca on NUZOLVENCE was triggered in October 2026, with payment due in October 2028\. CEO Pavel Raifeld said the company remains on track for its 2026 guidance of at least $150 million in U.S. net product sales.

Because the reserve release was a one-time item, the third-quarter tax benefit will not repeat in the same form.

### Sources

- [10-Q Filing — Innoviva (INVA)](https://www.sec.gov/Archives/edgar/data/0001080014/000119312526447384/inva-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Innoviva (INVA), Q2 FY2026 filed 2026-08-05 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001080014/000119312526335235/inva-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, d177079dex991.htm) — Innoviva, filed 2026-11-04](https://www.sec.gov/Archives/edgar/data/0001080014/000119312526447366/d177079dex991.htm?ref=bullished.co) — SEC EDGAR
- [Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611041605BIZWIRE%5FUSPRX%5F%5F%5F%5F20261104%5FBW246173-1&ref=bullished.co) — Financial Times
- [Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates](https://finance.yahoo.com/markets/stocks/articles/pfizer-pfe-surpasses-q3-earnings-120002762.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [INVA S-8及美國證券交易委員會申報文件 - Yahoo 財經](https://hk.finance.yahoo.com/sec-filing/INVA/0001193125-26-204249%5F1080014/?ref=bullished.co) — Yahoo Finance

### More on Innoviva

- [Innoviva Posts $73.9 Million Quarterly Loss As Armata Stake Drops, Even With U.S. Drug Sales Up 45%](https://www.bullished.co/innoviva-posts-73-9-million-quarterly-loss-as-armata-stake-drops-even-with-u-s-drug-sales-8a142d72/)

[All Innoviva (INVA) coverage →](https://www.bullished.co/tag/inva/)